HSCI / HK Connect Inclusion (Mar 2026): Lessons from a Sep 2025 Retrospective Event Study
A retrospective study of the Sep 2025 HK Connect event reveals where the alpha sat, when mean reversion kicks in, and how Connect inflows and...
396 Views
Hong Kong: IPO SPOTLIGHT - OVERVIEW 2025
Hong Kong is the top global destination for IPOs in 2025, with over HK $280 billion raised so far. Large scale A+H dual listings have surged this...
961 Views
China Healthcare Weekly (Nov.16) - Crazy Healthcare IPOs, Don't Bet on BD, Biokin HK IPO Delayed
​Investors're advised to focus on technical route over new BD deals from Chinese companies. Investors need to remain rational about healthcare...
433 Views
China Healthcare Weekly(Sep.21)-HK Biotechs Are Overvalued, Duality, Story Behind "Crazy" TransThera
​Investors in HK biotechs should consider taking profits as they are overvalued. Duality is under pressure of correction. TransThera’s shares...
726 Views
TransThera Sciences (Nanjing)Â IPO: Uniqueness of Lead Candidate Provides Comfort for Long-Term
TransThera Sciences got Phase 2 clinical trial approval for its lead drug candidate, Tinengotinib in combination with Fulvestrant for the treatment...
781 Views